The Effect of Perineural Dextrose Injection in Patients With Ulnar Neuropathy at the Elbow
Ulnar Neuropathies
About this trial
This is an interventional treatment trial for Ulnar Neuropathies
Eligibility Criteria
Inclusion Criteria:
- Age between 18-65 year-old.
- Neuropathic pain on the ulnar nerve distribution area for at least 1 months
- Diagnosis was confirmed using an electrophysiological studies and ultrasonography
Exclusion Criteria:
- History of trauma to the upper extremity
- Central or peripheral neurologic disease
- Electromyography (EMG)-proven carpal tunnel syndrome, radiculopathy or any other neuropathy
- Pregnancy or any systemic disease that might cause swelling on nerves (e.g., diabetes -mellitus, renal failure, and thyroid disease)
- USG-detected bifid or trifid median nerve, persistent median artery, or space-occupying lesions
Sites / Locations
- Basak Mansiz-Kaplan
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
dextrose group
control group
Procedure: Ultrasound-guided perineural injection with 5% dextrose. Ultrasound-guided perineural injection with 5% Dextrose (1cc) to ulnar nerve into the elbow, 2 and 4 cm before and after the elbow (total 5 cc). Drug: 5% Dextrose 5% Dextrose could decrease the release of CGRP (Calcitonin Gene Related Peptide) and substance P to reduce the nerve inflammation
Procedure: Perineural injection with normal saline Ultrasound-guided perineural injection with normal saline (1cc) to ulnar nerve into the elbow, 2 and 4 cm before and after the elbow (total 5 cc). Drug: Normal Saline Normal saline is safe for perineural injection.